Comité économique des produits de santé

Comité économique des produits de santé
Name	Comité économique des produits de santé
Formation	1990s
Headquarters	Paris
Region served	France
Membership	government appointees, experts
Leader title	President

Comité économique des produits de santé The Comité économique des produits de santé is a French advisory committee that evaluates pharmaceutical and medical device pricing and reimbursement, reporting to Ministry of Health (France), interacting with Haute Autorité de Santé, Direction générale de la Santé, Caisse Nationale d'Assurance Maladie, and stakeholders across Paris, Brussels, and international agencies such as World Health Organization, European Commission, and Organisation for Economic Co-operation and Development. Its analyses influence decisions by bodies like Conseil d'État, Assemblée nationale, Sénat (France), and private actors including Sanofi, Pfizer, and Roche. The committee's remit intersects with laws such as the Code de la santé publique, directives from European Medicines Agency, and agreements negotiated with unions like CFDT and CGT.

History

The committee was established amid reforms influenced by cases handled in Conseil d'État, debates in Assemblée nationale, and reports from Cour des comptes, with antecedents in consultative groups linked to Ministère des Affaires sociales and policy shifts after rulings involving European Court of Justice, Conseil constitutionnel, and the implementation of Directive 2011/24/EU. Early engagement included collaborations with Comité économique des produits de santé-adjacent entities such as Haute Autorité de Santé and partnerships with industry actors like AstraZeneca during pricing disputes that echoed disputes seen in United Kingdom and Germany. Over time, it adapted to frameworks set by Loi HPST, regulatory trends from European Medicines Agency, and recommendations from Organisation for Economic Co-operation and Development on health technology assessment.

Organization and Membership

The committee's structure mirrors advisory boards in agencies like Haute Autorité de Santé, with a president appointed by Ministre des Solidarités et de la Santé, and members drawn from institutions such as Caisse Nationale d'Assurance Maladie, Agence nationale de sécurité du médicament et des produits de santé, academic centers such as Collège de France, Université Paris-Saclay, and representatives from industry associations like Leem. Membership often includes economists affiliated with INSEE, legal experts connected to Conseil d'État, clinicians from hospitals like Assistance Publique–Hôpitaux de Paris, and patient advocates linked to France Assos Santé. Working groups can feature liaisons from European Commission, Organisation for Economic Co-operation and Development, and pharmaceutical firms including Novartis and Johnson & Johnson.

Mandate and Functions

Mandated by provisions of the Code de la santé publique and policy guidance from Ministère des Solidarités et de la Santé, the committee conducts health technology assessment in concert with Haute Autorité de Santé, undertakes pharmacoeconomic evaluations for companies such as Sanofi and GlaxoSmithKline, advises on reimbursement lists affecting hospitals like Hôpital Necker–Enfants Malades, and informs pricing agreements negotiated with insurers like Mutualité Française and public payers represented by Caisse Nationale d'Assurance Maladie. Functions include assessing clinical benefit, cost-effectiveness, and budget impact in contexts framed by cases before Conseil d'État and legislative scrutiny by Sénat (France). It also coordinates with European networks including European Medicines Agency and participates in cross-border pricing dialogues involving Germany, Italy, and Spain.

Decision-Making Process

Decisions are reached through expert panels resembling procedures at Haute Autorité de Santé and rely on dossiers submitted by manufacturers such as Roche or Pfizer, economic models from research units at INSERM and CNRS, and legal reviews linked to Conseil d'État precedents. Meetings follow protocols established in ministerial circulars and may involve consultation with stakeholders like Leem, patient groups such as France Assos Santé, and hospital federations including Fédération hospitalière de France. Outcomes feed into ministerial decrees signed by the Ministre des Solidarités et de la Santé and can be subject to appeals lodged before Tribunal administratif de Paris or the Conseil d'État.

Influence on Health Policy and Pricing

The committee shapes pricing through recommendations that inform negotiations with manufacturers including Novartis, AstraZeneca, and Bristol-Myers Squibb and by guiding reimbursement decisions enforced by Caisse Nationale d'Assurance Maladie and hospitals in the Assistance Publique–Hôpitaux de Paris network. Its evaluations have affected national policies debated in the Assemblée nationale and influenced transnational pricing approaches discussed at European Commission forums and in analyses by the Organisation for Economic Co-operation and Development. Through links with Haute Autorité de Santé and Agence nationale de sécurité du médicament et des produits de santé, the committee's guidance informs market access strategies of multinational firms such as Johnson & Johnson and GlaxoSmithKline.

Criticisms and Controversies

Critics from parties including members of Assemblée nationale, consumer groups like UFC-Que Choisir, and unions such as CGT have challenged the committee over perceived conflicts involving industry representatives from Leem and pharmaceutical companies like Sanofi and Pfizer. Legal challenges have been brought before Conseil d'État and Tribunal administratif de Paris citing transparency concerns echoing scandals that involved multinational corporations such as GlaxoSmithKline in other jurisdictions. Academic critiques from researchers at INSERM and Université Paris-Saclay have questioned methodological choices compared to practices endorsed by European Medicines Agency and Organisation for Economic Co-operation and Development, while patient associations like France Assos Santé have lobbied for greater involvement and clearer safeguards against capture by industry actors.

Category:Health policy in France